Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa Sells 10,000 Shares

Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa sold 10,000 shares of Calidi Biotherapeutics stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.62, for a total transaction of $16,200.00. Following the completion of the transaction, the chief executive officer now directly owns 66,712 shares in the company, valued at approximately $108,073.44. This represents a 13.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Calidi Biotherapeutics Trading Down 16.8 %

Shares of CLDI opened at $1.44 on Thursday. Calidi Biotherapeutics, Inc. has a one year low of $0.73 and a one year high of $19.70. The stock has a fifty day moving average price of $1.68.

Calidi Biotherapeutics (NYSE:CLDI) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.20. On average, research analysts expect that Calidi Biotherapeutics, Inc. will post -4.48 EPS for the current fiscal year.

Institutional Trading of Calidi Biotherapeutics

An institutional investor recently raised its position in Calidi Biotherapeutics stock. RS Crum Inc. increased its position in shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 2,327.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 263,470 shares of the company’s stock after purchasing an additional 252,616 shares during the period. RS Crum Inc. owned about 0.52% of Calidi Biotherapeutics worth $53,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.